2021
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, Loftis LL, Tarquinio KM, Singh AR, Heidemann SM, Soma VL, Riggs BJ, Fitzgerald JC, Kong M, Doymaz S, Giuliano JS, Keenaghan MA, Hume JR, Hobbs CV, Schuster JE, Clouser KN, Hall MW, Smith LS, Horwitz SM, Schwartz SP, Irby K, Bradford TT, Maddux AB, Babbitt CJ, Rowan CM, McLaughlin GE, Yager PH, Maamari M, Mack EH, Carroll CL, Montgomery VL, Halasa NB, Cvijanovich NZ, Coates BM, Rose CE, Newburger JW, Patel MM, Randolph AG. Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. New England Journal Of Medicine 2021, 385: 23-34. PMID: 34133855, PMCID: PMC8220972, DOI: 10.1056/nejmoa2102605.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesCombined Modality TherapyCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleGlucocorticoidsHospitalizationHumansImmunoglobulins, IntravenousImmunomodulationInfantLogistic ModelsMalePropensity ScorePublic Health SurveillanceShockSystemic Inflammatory Response SyndromeTreatment OutcomeVentricular Dysfunction, LeftYoung AdultConceptsIntravenous immune globulinMultisystem inflammatory syndromeCardiovascular dysfunctionDay 2Immunomodulatory therapyInflammatory syndromePrimary outcomeInitial treatmentLower riskRisk of feverReal-world effectivenessYears of agePropensity-score matchingImmunomodulatory medicationsVasopressor useVentricular dysfunctionAdjunctive therapyComposite outcomeImmune globulinSecondary outcomesAdjunctive treatmentRecurrent feverInverse probability weightingDay 1Glucocorticoids
2020
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jaggi P, Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan MA, Alharash H, Doymaz S, Clouser KN, Giuliano JS, Gupta A, Parker RM, Maddux AB, Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS, Tenforde MW, Carroll CL, Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado Munoz A, Hobbs CV, Marohn KL, Halasa NB, Patel MM, Randolph AG. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. New England Journal Of Medicine 2020, 383: 334-346. PMID: 32598831, PMCID: PMC7346765, DOI: 10.1056/nejmoa2021680.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBetacoronavirusCenters for Disease Control and Prevention, U.S.ChildCoronavirus InfectionsCOVID-19Critical CareFemaleGlucocorticoidsHumansImmunoglobulins, IntravenousImmunomodulationInflammationLength of StayMaleMucocutaneous Lymph Node SyndromePandemicsPneumonia, ViralProspective StudiesRespiration, ArtificialRetrospective StudiesSARS-CoV-2Systemic Inflammatory Response SyndromeUnited StatesConceptsMultisystem inflammatory syndromeInflammatory syndromeSARS-CoV-2Antibody testingSevere acute respiratory syndrome coronavirus 2Kawasaki disease-like featuresAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Coronary artery aneurysmsIntravenous immune globulinMultisystem organ involvementEvidence of infectionOrgan system involvementSyndrome coronavirus 2Reverse transcriptase-polymerase chain reactionCoronavirus disease 2019Life-threatening illnessPediatric health centersPublic health implicationsImmunomodulating therapiesVasoactive supportImmune globulinMedian durationMost patientsOrgan involvement